Company intelligence / Profile preview

Polybiomics

Berkeley, California, United Stateswashingtontechnology.org ↗

Ownership: Private
Development stage: Preclinical

Overview

Polybiomics has developed a proprietary instrument that allows researchers to obtain multiple, simultaneous measurements from living biological samples. This technology integrates direct information about evolving samples in real time and is positioned to transform drug discovery processes in pharma as well as product development for clinical and agricultural applications. The company’s approach accelerates the development of better therapies by providing richer data on live cells[3][4][5].

Therapeutic areas: Other
Modalities: Live cell analysisReal-time cellular feature measurementPlatform technology (not a therapeutic developer per se)
Industry: Drug Discovery Services

Partnerships

No major pharmaceutical or biotech partnerships publicly listed.

Beyond the preview

Go deeper on Polybiomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polybiomics.

Explore the full profile